These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37839467)

  • 1. Matrix Gla Protein, a New Target Fighting Against Fibrosis of Nonalcoholic Steatohepatitis?
    Hinz K; Ding WX
    Cell Mol Gastroenterol Hepatol; 2023; 16(6):1034-1035. PubMed ID: 37839467
    [No Abstract]   [Full Text] [Related]  

  • 2. Predictors of nonalcoholic steatohepatitis and significant fibrosis in non-obese nonalcoholic fatty liver disease.
    Kim D; Kim W; Joo SK; Kim JH; Harrison SA; Younossi ZM; Ahmed A
    Liver Int; 2019 Feb; 39(2):332-341. PubMed ID: 30298568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of sarcopenia with steatohepatitis and advanced liver fibrosis in non-alcoholic fatty liver disease: a meta-analysis.
    Yu R; Shi Q; Liu L; Chen L
    BMC Gastroenterol; 2018 Apr; 18(1):51. PubMed ID: 29673321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease.
    Tada T; Kumada T; Toyoda H; Saibara T; Ono M; Kage M
    Biomarkers; 2018; 23(4):328-334. PubMed ID: 29308929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology.
    Yilmaz Y; Eren F
    Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):43-46. PubMed ID: 30134384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease.
    Kim TH; Banini BA; Asumda FZ; Campbell NA; Hu C; Moser CD; Shire AM; Han S; Ma C; Krishnan A; Mounajjed T; White TA; Gores GJ; LeBrasseur NK; Charlton MR; Roberts LR
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G333-G344. PubMed ID: 32683952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with Oxidized Phospholipids Directly Inhibits Nonalcoholic Steatohepatitis and Liver Fibrosis Without Affecting Steatosis.
    Mendel I; Yacov N; Shoham A; Ishai E; Breitbart E
    Dig Dis Sci; 2016 Sep; 61(9):2545-53. PubMed ID: 27074921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice.
    Onoyama T; Koda M; Okamoto T; Kishina M; Matono T; Sugihara T; Murawaki Y
    Mol Med Rep; 2015 Nov; 12(5):6895-902. PubMed ID: 26397061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ron Receptor Signaling Ameliorates Hepatic Fibrosis in a Diet-Induced Nonalcoholic Steatohepatitis Mouse Model.
    Allen J; Zhang J; Quickel MD; Kennett M; Patterson AD; Hankey-Giblin PA
    J Proteome Res; 2018 Sep; 17(9):3268-3280. PubMed ID: 30091925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninvasive Assessment of Nonalcoholic Steatohepatitis and Nonalcoholic Steatohepatitis-Related Fibrosis: Is There a Role for Cytokeratin 18?
    Xanthakos SA
    J Pediatr Gastroenterol Nutr; 2016 Aug; 63(2):167-8. PubMed ID: 26960172
    [No Abstract]   [Full Text] [Related]  

  • 11. Will Studies in Nonalcoholic Steatohepatitis Help Manage Alcoholic Steatohepatitis?
    Sundaram V; Morgan TR
    Clin Liver Dis; 2019 Feb; 23(1):157-165. PubMed ID: 30454829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Chow MD; Lee YH; Guo GL
    Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: new trends and role of ultrasonography.
    Tada T; Nishimura T; Yoshida M; Iijima H
    J Med Ultrason (2001); 2020 Oct; 47(4):511-520. PubMed ID: 33089412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Awareness of nonalcoholic steatohepatitis and associated practice patterns of primary care physicians and specialists.
    Polanco-Briceno S; Glass D; Stuntz M; Caze A
    BMC Res Notes; 2016 Mar; 9():157. PubMed ID: 26969270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of
    Luukkonen PK; Sakuma I; Gaspar RC; Mooring M; Nasiri A; Kahn M; Zhang XM; Zhang D; Sammalkorpi H; Penttilä AK; Orho-Melander M; Arola J; Juuti A; Zhang X; Yimlamai D; Yki-Järvinen H; Petersen KF; Shulman GI
    Proc Natl Acad Sci U S A; 2023 Jan; 120(4):e2217543120. PubMed ID: 36669104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic fatty liver disease: a systematic review.
    Rinella ME
    JAMA; 2015 Jun; 313(22):2263-73. PubMed ID: 26057287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 18. Nonalcoholic fatty liver disease: one entity, multiple impacts on liver health.
    Fierbinteanu-Braticevici C; Sinescu C; Moldoveanu A; Petrisor A; Diaconu S; Cretoiu D; Braticevici B
    Cell Biol Toxicol; 2017 Feb; 33(1):5-14. PubMed ID: 27680752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nitro-fatty acids protect against steatosis and fibrosis during development of nonalcoholic fatty liver disease in mice.
    Rom O; Xu G; Guo Y; Zhu Y; Wang H; Zhang J; Fan Y; Liang W; Lu H; Liu Y; Aviram M; Liu Z; Kim S; Liu W; Wang X; Chen YE; Villacorta L
    EBioMedicine; 2019 Mar; 41():62-72. PubMed ID: 30772307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sparcl1 promotes nonalcoholic steatohepatitis progression in mice through upregulation of CCL2.
    Liu B; Xiang L; Ji J; Liu W; Chen Y; Xia M; Liu Y; Liu W; Zhu P; Jin Y; Han Y; Lu J; Li X; Zheng M; Lu Y
    J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34651580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.